vs
安捷伦科技（A）与Enhabit, Inc.（EHAB）财务数据对比。点击上方公司名可切换其他公司
安捷伦科技的季度营收约是Enhabit, Inc.的6.6倍（$1.8B vs $270.4M）。安捷伦科技净利率更高（17.0% vs -14.3%，领先31.3%）。安捷伦科技同比增速更快（7.0% vs 4.7%）。安捷伦科技自由现金流更多（$175.0M vs $3.3M）。过去两年安捷伦科技的营收复合增速更高（6.9% vs 1.5%）
安捷伦科技是全球知名的生命科学、诊断与应用化学领域解决方案提供商，旗下生命科学与应用市场业务板块提供液相色谱系统及组件、液相色谱质谱联用系统、气相色谱设备、电感耦合等离子体质谱仪、原子吸收仪等多种分析检测仪器，服务全球各领域客户。
Enhabit, Inc.是总部位于美国得克萨斯州达拉斯的居家护理与临终关怀服务提供商，目前在全美34个州运营255个居家护理站点与110个临终关怀站点，业务集中在得克萨斯、亚拉巴马、佛罗里达、佐治亚、俄克拉荷马与密西西比，是美国第四大居家护理服务商，也是头部临终关怀服务商，2022年由恩compass健康拆分居家护理与临终关怀业务拆分成立。
A vs EHAB — 直观对比
营收规模更大
A
是对方的6.6倍
$270.4M
营收增速更快
A
高出2.2%
4.7%
净利率更高
A
高出31.3%
-14.3%
自由现金流更多
A
多$171.7M
$3.3M
两年增速更快
A
近两年复合增速
1.5%
损益表 — Q1 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.8B | $270.4M |
| 净利润 | $305.0M | $-38.7M |
| 毛利率 | 52.6% | — |
| 营业利润率 | 19.6% | -12.3% |
| 净利率 | 17.0% | -14.3% |
| 营收同比 | 7.0% | 4.7% |
| 净利润同比 | -4.1% | 15.9% |
| 每股收益（稀释后） | $1.07 | $-0.76 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AEHAB
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.9B | $270.4M | ||
| Q3 25 | $1.7B | $263.6M | ||
| Q2 25 | $1.7B | $266.1M | ||
| Q1 25 | $1.7B | $259.9M | ||
| Q4 24 | $1.7B | $258.2M | ||
| Q3 24 | $1.6B | $253.6M | ||
| Q2 24 | $1.6B | $260.6M |
净利润AEHAB
| Q1 26 | $305.0M | — | ||
| Q4 25 | $434.0M | $-38.7M | ||
| Q3 25 | $336.0M | $11.1M | ||
| Q2 25 | $215.0M | $5.2M | ||
| Q1 25 | $318.0M | $17.8M | ||
| Q4 24 | $351.0M | $-46.0M | ||
| Q3 24 | $282.0M | $-110.2M | ||
| Q2 24 | $308.0M | $-200.0K |
毛利率AEHAB
| Q1 26 | 52.6% | — | ||
| Q4 25 | 53.2% | — | ||
| Q3 25 | 51.1% | — | ||
| Q2 25 | 51.9% | — | ||
| Q1 25 | 53.5% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 54.2% | — | ||
| Q2 24 | 54.4% | — |
营业利润率AEHAB
| Q1 26 | 19.6% | — | ||
| Q4 25 | 23.8% | -12.3% | ||
| Q3 25 | 20.7% | 6.4% | ||
| Q2 25 | 18.0% | 6.3% | ||
| Q1 25 | 22.4% | 6.1% | ||
| Q4 24 | 24.0% | -16.0% | ||
| Q3 24 | 21.1% | -38.6% | ||
| Q2 24 | 23.1% | 4.3% |
净利率AEHAB
| Q1 26 | 17.0% | — | ||
| Q4 25 | 23.3% | -14.3% | ||
| Q3 25 | 19.3% | 4.2% | ||
| Q2 25 | 12.9% | 2.0% | ||
| Q1 25 | 18.9% | 6.8% | ||
| Q4 24 | 20.6% | -17.8% | ||
| Q3 24 | 17.9% | -43.5% | ||
| Q2 24 | 19.6% | -0.1% |
每股收益（稀释后）AEHAB
| Q1 26 | $1.07 | — | ||
| Q4 25 | $1.53 | $-0.76 | ||
| Q3 25 | $1.18 | $0.22 | ||
| Q2 25 | $0.75 | $0.10 | ||
| Q1 25 | $1.11 | $0.35 | ||
| Q4 24 | $1.23 | $-0.92 | ||
| Q3 24 | $0.97 | $-2.20 | ||
| Q2 24 | $1.05 | $0.00 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.8B | $43.6M |
| 总债务越低越好 | $3.0B | $426.0M |
| 股东权益账面价值 | $6.9B | $534.0M |
| 总资产 | $12.8B | $1.2B |
| 负债/权益比越低杠杆越低 | 0.44× | 0.80× |
8季度趋势，按日历期对齐
现金及短期投资AEHAB
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.8B | $43.6M | ||
| Q3 25 | $1.5B | $56.9M | ||
| Q2 25 | $1.5B | $37.1M | ||
| Q1 25 | $1.5B | $39.5M | ||
| Q4 24 | $1.3B | $28.4M | ||
| Q3 24 | $1.8B | $45.7M | ||
| Q2 24 | $1.7B | $28.5M |
总债务AEHAB
| Q1 26 | $3.0B | — | ||
| Q4 25 | $3.0B | $426.0M | ||
| Q3 25 | $3.4B | $441.5M | ||
| Q2 25 | $3.3B | $456.9M | ||
| Q1 25 | $3.3B | $467.3M | ||
| Q4 24 | $3.3B | $492.6M | ||
| Q3 24 | $2.1B | $502.9M | ||
| Q2 24 | $2.1B | $512.7M |
股东权益AEHAB
| Q1 26 | $6.9B | — | ||
| Q4 25 | $6.7B | $534.0M | ||
| Q3 25 | $6.4B | $566.8M | ||
| Q2 25 | $6.1B | $552.4M | ||
| Q1 25 | $6.0B | $543.2M | ||
| Q4 24 | $5.9B | $523.5M | ||
| Q3 24 | $5.9B | $566.1M | ||
| Q2 24 | $6.2B | $674.3M |
总资产AEHAB
| Q1 26 | $12.8B | — | ||
| Q4 25 | $12.7B | $1.2B | ||
| Q3 25 | $12.2B | $1.2B | ||
| Q2 25 | $12.2B | $1.2B | ||
| Q1 25 | $11.9B | $1.2B | ||
| Q4 24 | $11.8B | $1.2B | ||
| Q3 24 | $11.0B | $1.3B | ||
| Q2 24 | $10.9B | $1.4B |
负债/权益比AEHAB
| Q1 26 | 0.44× | — | ||
| Q4 25 | 0.45× | 0.80× | ||
| Q3 25 | 0.53× | 0.78× | ||
| Q2 25 | 0.55× | 0.83× | ||
| Q1 25 | 0.56× | 0.86× | ||
| Q4 24 | 0.57× | 0.94× | ||
| Q3 24 | 0.36× | 0.89× | ||
| Q2 24 | 0.34× | 0.76× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $268.0M | $4.4M |
| 自由现金流经营现金流 - 资本支出 | $175.0M | $3.3M |
| 自由现金流率自由现金流/营收 | 9.7% | 1.2% |
| 资本支出强度资本支出/营收 | 5.2% | 0.4% |
| 现金转化率经营现金流/净利润 | 0.88× | — |
| 过去12个月自由现金流最近4个季度 | $993.0M | $65.8M |
8季度趋势，按日历期对齐
经营现金流AEHAB
| Q1 26 | $268.0M | — | ||
| Q4 25 | $545.0M | $4.4M | ||
| Q3 25 | $362.0M | $37.8M | ||
| Q2 25 | $221.0M | $10.6M | ||
| Q1 25 | $431.0M | $17.9M | ||
| Q4 24 | $481.0M | $-4.1M | ||
| Q3 24 | $452.0M | $28.4M | ||
| Q2 24 | $333.0M | $9.6M |
自由现金流AEHAB
| Q1 26 | $175.0M | — | ||
| Q4 25 | $452.0M | $3.3M | ||
| Q3 25 | $259.0M | $36.2M | ||
| Q2 25 | $107.0M | $8.7M | ||
| Q1 25 | $334.0M | $17.6M | ||
| Q4 24 | $388.0M | $-4.7M | ||
| Q3 24 | $360.0M | $27.7M | ||
| Q2 24 | $230.0M | $8.9M |
自由现金流率AEHAB
| Q1 26 | 9.7% | — | ||
| Q4 25 | 24.3% | 1.2% | ||
| Q3 25 | 14.9% | 13.7% | ||
| Q2 25 | 6.4% | 3.3% | ||
| Q1 25 | 19.9% | 6.8% | ||
| Q4 24 | 22.8% | -1.8% | ||
| Q3 24 | 22.8% | 10.9% | ||
| Q2 24 | 14.6% | 3.4% |
资本支出强度AEHAB
| Q1 26 | 5.2% | — | ||
| Q4 25 | 5.0% | 0.4% | ||
| Q3 25 | 5.9% | 0.6% | ||
| Q2 25 | 6.8% | 0.7% | ||
| Q1 25 | 5.8% | 0.1% | ||
| Q4 24 | 5.5% | 0.2% | ||
| Q3 24 | 5.8% | 0.3% | ||
| Q2 24 | 6.5% | 0.3% |
现金转化率AEHAB
| Q1 26 | 0.88× | — | ||
| Q4 25 | 1.26× | — | ||
| Q3 25 | 1.08× | 3.41× | ||
| Q2 25 | 1.03× | 2.04× | ||
| Q1 25 | 1.36× | 1.01× | ||
| Q4 24 | 1.37× | — | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 1.08× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
A
| Service Other | $525.0M | 29% |
| Chemicaland Energy Market | $422.0M | 23% |
| Agilent Cross Lab | $273.0M | 15% |
| Environmentaland Forensics Market | $177.0M | 10% |
| Food Market | $166.0M | 9% |
| Academiaand Government Market | $130.0M | 7% |
| Applied Markets | $98.0M | 5% |
EHAB
| Third Party Payor Medicare | $111.6M | 41% |
| Third Party Payor Medicare Advantage | $67.5M | 25% |
| Hospice Segment | $63.6M | 24% |
| Third Party Payor Managed Care | $24.9M | 9% |
| Third Party Payor Medicaid | $1.7M | 1% |
